ARCHIVES

As FDA Weighs its Options on Morcellation, Debate Erupts Over Harvard Device Study

This article is from The Cancer Letter archive.

Vol. 40 No. 44 | November 21, 2014

Download PDF Visit The Full Archive

Related Articles

Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%

June 28, 2013

NCI Programs: New RAID Program Offers NCI Expertise In Drug Development

April 24, 1998

In Brief: NCI Scientist Accused Of Taking ‘Payoffs’ Forom Drug Firms; GM-CS Wins FDA Approval

March 15, 1991

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

November 28, 2003

NCI Evaluating PDQ Evaluation

September 1, 1989

Millers, Jensen, Bereblum Win $100,000 GM awards

June 6, 1980